WallStreetZenWallStreetZen

NASDAQ: KPTI
Karyopharm Therapeutics Inc Stock Ownership - Who owns Karyopharm Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Karyopharm Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Reshma RangwalaEVP Chief Medical Officer2026-03-025,066$9.41
$47.67kSell
Kristin AbateChief Accounting Officer2026-03-02559$9.41
$5.26kSell
Sohanya Roshan ChengEVP Chief Commercial Officer2026-03-024,604$9.41
$43.32kSell
Michael ManoEVP CLOSecretary2026-03-023,526$9.41
$33.18kSell
Richard A. PaulsonPresident and CEO2026-03-0212,361$9.41
$116.30kSell
Stuart PoultonEVP Chief Development Officer2026-03-025,101$9.41
$48.00kSell
Stuart PoultonEVP Chief Development Officer2026-02-17378$8.63
$3.26kSell
Lori MacOmberEVP CFO Treasurer2026-02-031,626$6.30
$10.24kSell
Kristin AbateChief Accounting Officer2026-01-2850$7.03
$351.50Sell
Kristin AbateChief Accounting Officer2026-01-21265$5.96
$1.58kSell

1 of 3

KPTI insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when KPTI insiders and whales buy or sell their stock.

KPTI Shareholders

What type of owners hold Karyopharm Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Chione Ltd88.63%16,258,079$136.57MInsider
Plio Ltd34.55%6,336,946$53.23MInsider
Marcin Czernik32.33%5,930,939$49.82MInsider
Deepika Pakianathan12.45%2,283,343$19.18MInsider
Sharon Shacham9.11%1,671,888$14.04MInsider
Michael Kauffman8.79%1,611,888$13.54MInsider
T Rowe Price Investment Management Inc8.13%1,491,409$12.53MInstitution
Opaleye Management Inc5.07%930,000$7.81MInstitution
Affinity Asset Advisors LLC4.85%889,575$7.47MInstitution
Vanguard Group Inc3.05%559,619$4.70MInstitution

1 of 3

KPTI vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
KPTI20.88%79.12%Net SellingNet Selling
VTVT2.07%97.93%Net Buying
ANTX24.11%62.00%Net SellingNet Selling
TLSA2.64%40.06%
ORMP27.78%57.87%
View Top Biotech Stocks

Karyopharm Therapeutics Stock Ownership FAQ

Who owns Karyopharm Therapeutics?

Karyopharm Therapeutics (NASDAQ: KPTI) is owned by 51.60% institutional shareholders, 195.49% Karyopharm Therapeutics insiders, and 0.00% retail investors. Chione Ltd is the largest individual Karyopharm Therapeutics shareholder, owning 16.26M shares representing 88.63% of the company. Chione Ltd's Karyopharm Therapeutics shares are currently valued at $125.67M.

If you're new to stock investing, here's how to buy Karyopharm Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.